Lead Product(s) : Amivantamab,Lazertinib,Dexamethasone
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Dexamethasone Reduces Infusion Reactions in EGFR-Mutated NSCLC Patients On RYBREVANT®
Details : Rybrevant (amivantamab) in combination with Lazcluze (lazertinib) and dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer.
Brand Name : Rybrevant
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 10, 2024
Lead Product(s) : Amivantamab,Lazertinib,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Amivantamab,Lazertinib,Dexamethasone
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
J&J's Chemotherapy-Free Treatment for Lung Cancer Gets US Approval
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is indicated in combination with Lazertinib for the treatment of Advanced or Metastatic Non-small Cell Lung Cancer.
Brand Name : Rybrevant
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 20, 2024
Lead Product(s) : Amivantamab,Lazertinib,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Amivantamab,Lazertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Amivantamab BLA Submitted to FDA for EGFR-Mutated Non-Small Cell Lung Cancer
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with Lazertinib for the treatment of Advanced or Metastatic Non-small Cell Lung Cancer.
Brand Name : Rybrevant
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 17, 2024
Lead Product(s) : Amivantamab,Lazertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Amivantamab,Lazertinib,Carboplatin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PALOMA-2 Shows Positive Results for Subcutaneous RYBREVANT® in EGFR-Mutated NSCLC
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with Lazertinib for the treatment of exon 19 deletions or L858R mutated NSCLC.
Brand Name : Rybrevant
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 03, 2024
Lead Product(s) : Amivantamab,Lazertinib,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Amivantamab,Lazertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Phase 3 PALOMA-3 Shows Five-Fold Reduction in Reactions with Amivantamab Injection
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with Lazertinib for the treatment of Advanced or Metastatic Non-small Cell Lung Cancer.
Brand Name : Rybrevant
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 31, 2024
Lead Product(s) : Amivantamab,Lazertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Amivantamab,Lazertinib,Carboplatin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
RYBREVANT® Plus Lazertinib Shows Longer PFS vs. Osimertinib in High-Risk NSCLC
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with Lazertinib for the treatment of EGFR-mutated NSCLC after failure of prior therapy.
Brand Name : Rybrevant
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 31, 2024
Lead Product(s) : Amivantamab,Lazertinib,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Amivantamab,Lazertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Janssen Submits Type II Extension for RYBREVANT and Lazertinib
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody evaluated with lazertinib for first-line treatment of patients with EGFR-mutated non-small cell lung cancer.
Brand Name : Rybrevant
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 08, 2024
Lead Product(s) : Amivantamab,Lazertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lazertinib,Amivantamab-vmjw
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : JNJ-73841937 (lazertinib) is an oral, third-generation, brain-penetrant EGFR TKI that targets both the T790M mutation. It is under phase 3 clinical development in combination with Rybrevant (amivantamab) for the treatment of EGFR-mutated non-small cell l...
Brand Name : JNJ-73841937
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 21, 2023
Lead Product(s) : Lazertinib,Amivantamab-vmjw
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Amivantamab,Lazertinib,Carboplatin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Rybrevant (amivantamab) is a fully-human bispecific antibody targeting EGFR and MET with immune cell-directing activity. It is being evaluated in combination with lazertinib for the treatment of patients with EGFR-mutated non-small cell lung cancer.
Brand Name : Rybrevant
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 21, 2023
Lead Product(s) : Amivantamab,Lazertinib,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Amivantamab,Lazertinib,Pemetrexed
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with Lazertinib & chemotherapy for the treatment of adult patients with advanced egfr-mutated non-small cell lung cancer after failure of prior th...
Brand Name : Rybrevant
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 23, 2023
Lead Product(s) : Amivantamab,Lazertinib,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?